Levels of antigen processing machinery components in dendritic cells generated for vaccination of HIV-1+ subjects

AIDS

Volumn 21, Issue 13, 2007, Pages 1683-1692

  Connolly, Nancy ^a   Riddler, Sharon ^a   Stanson, Joanna ^b   Gooding, William ^b   Rinaldo, Charles R ^a,b,c   Ferrone, Soldano ^d   Whiteside, Theresa L ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Antigen processing machinery; Dendritic cells; HIV 1; Immunity to HIV 1; Peptide presentation

Indexed keywords

BETA 2 MICROGLOBULIN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS PROTEIN;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIVIRAL THERAPY; ARTICLE; CELL MATURATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; DENDRITIC CELL; ENZYME LINKED IMMUNOSPOT ASSAY; EPSTEIN BARR VIRUS; EX VIVO STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION; INFLUENZA VIRUS A; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINATION;

ADULT; AIDS VACCINES; ANTIGEN PRESENTATION; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; HIV INFECTIONS; HIV-1; HLA-A2 ANTIGEN; HUMANS; IMMUNOPHENOTYPING; INTERFERON TYPE II; INTERLEUKIN-12; MIDDLE AGED; MONOCYTES; VACCINATION;

EID: 34547788907     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32825eabbc     Document Type: Article

References (34)

1. Srivastava PK. Therapeutic cancer vaccines. Curr Opin Immunol 2006; 18:201-205.
2. Connolly N, Riddler S, Wilson C, Whiteside T, Rinaldo C. Dendritic cell-HIV peptide therapeutic vaccination is safe and immunogenic in HIV-infected subjects with virologic suppression. Thirteenth Conference on Retroviruses and Opportunistic Infections. Denver, CO, February 2006 [abstract 486].
3. Lu W, Arraes LC, Ferreira WT, Andrieu JM. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med 2004; 10:1359-1365.
4. Garcia F, Lejeune M, Climent N, Gil C, Alcami J, Morente V, et al. Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection. J Infect Dis 2005; 191:1680-1685.
5. Ide F, Nakamura T, Tomizawa M, Kawana-Tachikawa A, Odawara T, Hosoya N, et al. Peptide-loaded dendritic-cell vaccination followed by treatment interruption for chronic HIV-1 infection: a phase I trial. J Med Virol 2006; 78:711-718.
6. Piquet V, Blauvelt A. Essential roles for dendritic cells in the pathogenesis and potential treatment of HIV disease. J Invest Derm 2002; 119:365-369.
7. Chougnet C, Cohen SS, Kawamura T, Landay AL, Kessler HA, Thomas E, et al. Normal immune function of monocyte-derived dendritic cells from HIV-infected individuals: implications for immunotherapy. J Immunol 1999; 163:1666-1673.
8. Blazevic V, Jankelevich S, Steinberg SM, Jacobsen F, Yarchoan R, Shearer GM. Highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children: analysis of cellular immune responses. Clin Diagn Lab Immunol 2001; 8:943-948.
9. Sapp M, Engelmayer J, Larsson M, Granelli-Piperno A, Steinman R, Bhardwaj N. Dendritic cells generated from blood monocytes of HIV-1 patients are not infected and act as competent antigen presenting cells eliciting potent T-cell responses. Immunol Let 1999; 66:121-128.
10. Fan Z, Huang XL, Zheng L, Wilson C, Borowski L, Liebmann J, et al. Cultured blood dendritic cells retain HIV-1 antigenpresenting capacity for memory CTL during progressive HIV-1 infection. J Immunol 1997; 159:4973-4982.
11. Fan Z, Huang SX, Borowski L, Mellors JW, Rinaldo CR Jr. Restoration of antihuman immunodeficiency virus type 1 (HIV-1) responses in CD8+ T cells from late-stage patients on prolonged antiretroviral therapy by stimulation in vitro with HIV-1 protein-loaded dendritic cells. J Virol 2001; 75:4413-4419.
12. Blauvelt A, Clerici M, Lucey DR, Steinberg SM, Yarchoan R, Walker R. Functional studies of epidermal Langerhans cells and blood monocytes in HIV-infected persons. J Immunol 1995; 154:3506-3515.
13. Blauvelt A, Chougnet C, Shearer GM, Katz SI. Modulation of T cell responses to recall antigens presented by Langerhans cells in HIV-discordant identical twins by antiinterleukin (IL)-10 antibodies and IL-12. J Clin Invest 1996; 97:1550-1555.
14. Kawamura T, Gatanaga H, Borris DL, Connors M, Mitsuya H, Blauvelt A. Decreased stimulation of CD4+ T cell proliferation and IL-2 production by highly enriched populations of HIV-infected dendritic cells. J Immunol 2003; 170:4260-4266.
15. Granelli-Piperno A, Golebiowska A, Trumpfheller C, Siegal FP, Steinman RM. HIV-1-infected monocyte-derived dendritic cells do not undergo maturation but can elicit IL-10 production and T cell regulation. Pro Nat Acad Sci USA 2004; 101:7669-7674.
16. Servet C, Zitvogel L, Hosmalin A. Dendritic cells in innate immune responses against HIV. Curr Mol Med 2002; 2:739-756.
17. Sant A, Yewdell J. Antigen processing and recognition. Curr Opin Immunol 2003; 15:66-68.
18. Li J, Schuler-Thurner B, Schuler G, Huber C, Seliger B. Bipartite regulation of different components of the MHC class I antigen-processing machinery during dendritic cell maturation. Int Immunol 2001; 13:1515-1523.
19. Ferris RL, Whiteside TL, Ferrone S. Immune escape associated with functional defects in antigen processing machinery in head and neck cancer. Clin Cancer Res 2006; 12:3890-3895.
20. Ackerman AL, Cresswell P. Regulation of MHC class I transport in human dendritic cells and the dendritic-like cell line KG-1. J Immunol 2003; 170:4178-4188.
21. Whiteside TL, Stanson J, Shurin MR, Ferrone S. Antigen-processing machinery in human dendritic cells: up-regulation by maturation and down-regulation by tumor cells. J Immunol 2004; 173:1526-1534.
22. Connolly N, Whiteside TL, Wilson C, Kondragunta V, Rinaldo CR, Riddler SA. Therapeutic immunization of HIV-1-infected individuals with mature, HIV-1 peptide loaded dendritic cells. AIDS, Submitted, 2007.
23. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994; 179:1109-1118.
24. Whiteside TL, Zhao Y, Tsukishiro T, Elder EM, Gooding W, Baar J. Enzyme-linked immunospot, cytokine flow cytometry, and tetramers in the detection of T-cell responses to a dendritic cell-based multipeptide vaccine in patients with melanoma. Clin Cancer Res 2003; 9:641-649.
25. Ogino T, Wang X, Kato S, Miyokawa N, Harabuchi Y, Ferrone S. Endoplasmic reticulum chaperone-specific monoclonal antibodies for flow cytometry and immunohistochemical staining. Tissue Antigens 2003; 62:385-393.
26. Bandoh N, Ogino T, Cho HS, Hur SY, Shen JJ, Wang X, et al. Development and characterization of human constitutive proteasome and immunoproteasome subunit-specific monoclonal antibodies. Tissue Antigens 2005; 66:185-194.
27. Wang X, Campoli M, Cho HS, Ogino T, Bandoh N, Shen J, et al. A method to generate antigen-specific mAb capable of staining formalin-fixed, paraffin-embedded tissue sections. J Immunol Meth 2005; 299:139-151.
28. Lampson LA, Fisher CA, Whelan JP. Striking paucity of HLA-A, B, C and beta 2-microglobulin on human neuroblastoma cell lines. J Immunol 1983; 30:2471-2478.
29. Hoffmann TK, Muller-Berghaus J, Ferris RL, Johnson JT, Storkus WJ, Whiteside TL. Alterations in the frequency of dendritic cell subsets in the peripheral circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2002; 8:1787-1793.
30. Huang XL, Fan Z, Colleton BA, Buchli R, Li H, Hildebrand WH, et al. Processing and presentation of exogenous HLA class I peptides by dendritic cells from human immunodeficiency virus type 1-infected persons. J Virol 2005; 79:3052-3062.
31. Carbonneil C, Donkova-Petrini V, Aouba A, Weiss L. Defective dendritic cell function in HIV-infected patients receiving effective highly active antiretroviral therapy: neutralization of IL-10 production and depletion of CD4RCD25R T cells restore high levels of HIV-specific CD4R T cell responses induced by dendritic cells generated in the presence of IFN-alpha. J Immunol 2004; 172:7832-7840.
32. Zhao XQ, Huang XL, Gupta P, Borowski L, Fan Z, Watkins SC, et al. Induciton of antihuman immunodeficiency virus type 1 (HIV-1) CD8(+) and CD4(+) T-cell reactivity by dendritic cells loaded with HIV-1 X4-infected apoptotic cells. J Virol 2002; 76:3007-3014.
33. Laybarger L, Wang X, Harris M, Hansen TH. Viral immune evasion molecules attack the ER peptide loading complex and exploit ER-associated degradation pathways. Curr Opin Immunol 2005; 17:71-78.
34. Mailliard RB, Wankowicz-Kalinska A, Cai A, Wesa A, Hilkens CM, Kapsenberg ML, et al. Alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res 2004; 64:5934-5937.